Rumor Has It: Expect Valeant Divestitures?

The plagued specialty pharma has been rumored to have at least one suitor, but analysts are skeptical and expect multiple divestitures will be required if the company is going to gain back some of its losses.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip